Haleon (HLN) Assets (2021 - 2026)

Haleon's (HLN) quarterly Assets came in at $43.7 billion in Q2 2026, little changed on a QoQ basis from $43.7 billion in Q4 2025.

Haleon (HLN) Assets (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Assets data on file, last reported at $43.7 billion in Q2 2026.

Quarterly Assets changed N/A year-over-year to $43.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.7 billion (changed N/A YoY) and the FY2025 annual result came in at $43.4 billion, down 1.05% from the prior year.
Assets was little changed at $43.7 billion in Q2 2026, from $43.7 billion in the prior quarter.
In the past five years, Assets ranged from a high of $56.7 billion in Q2 2022 to a low of $40.8 billion in Q4 2022.
A 5-year average of $44.5 billion and a median of $43.2 billion in 2023 frame the typical range for Assets.
Annual changes were most pronounced in 2023 — Assets fell 24.57% — and 2024, when it climbed 4.2%.
Tracing HLN's Assets over 5 years: stood at $40.8 billion in 2022, then climbed by 3.51% to $42.3 billion in 2023, then gained by 4.2% to $44.0 billion in 2024, then declined by 0.74% to $43.7 billion in 2025, then declined by 0.01% to $43.7 billion in 2026.
The last three Assets figures came in at $43.7 billion (Q2 2026), $43.7 billion (Q4 2025), and $44.0 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	43.71 Bn
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	39.86 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	15.08 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	98.27 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	7.22 Bn
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	35.04 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	5.36 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	13.56 Bn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	6.18 Bn
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	4.39 Bn

Download Data